Analysis of efficacy obtained with a trivalent inactivatedHaemophilus parasuisserovars 4, 5, and 12 vaccine and commercial vaccines against Glässer's disease in piglets.
The objective of this study was to assess the efficacy of a trivalent inactivatedHaemophilus parasuisserovars 4, 5, and 12 vaccine with polymeric adjuvant gel (GEL) and commercial vaccines against Glässer's disease in piglets. Commercial vaccines containing inactivatedH. parasuisserovars 4 and 5 (China), inactivatedH. parasuisserovars 1 and 6 (Spain), and inactivatedH. parasuisserovar 5 (USA) were also evaluated. Our results demonstrated that the trivalent inactivatedH. parasuisserovars 4, 5, and 12 vaccine with GEL adjuvant can provide better protection against the 3 most common pathogenic serovars circulating in China than other commercial vaccines tested. Our findings also indicated that inactivatedH. parasuisserovars 1 and 6 vaccine cross-protects piglets againstH. parasuisserovars 4 and 5; inactivatedH. parasuisserovar 5 vaccine cross-protects piglets againstH. parasuisserovar 4 challenge; but none of the commercial vaccines tested in this study protected piglets againstH. parasuisserovar 12. Our results provide a basis for further identification of common protective antigens that can induce cross-protection against heterogeneous serovars.
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Zhanqin
Z
Zhao
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Huisheng
H
Liu
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Yun
Y
Xue
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Kunpeng
K
Chen
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Zhijun
Z
Liu
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Qiao
Q
Xue
Laboratory of Veterinary Microbiology, College of Animal Science and Technology (Zhao, Liu, Chen, Q. Xue, Wang); Laboratory of Medical Engineering, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China (Y. Xue).
Chen
C
Wang
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D005260:Female; D006192:Haemophilus Infections / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D044137:Haemophilus parasuis / Q000145:classification*; D065288:Serogroup; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated